Source intravenous injection metronidazole for Internal Medicine Surgery and Antibacterial Needs

Strategic Sourcing Guide for Intravenous Metronidazole Procurement

Understanding Product Specifications and Formulations

When sourcing intravenous injection metronidazole, buyers must first navigate a complex landscape of product attributes that define the physical and chemical nature of the supply. The core keyword implies a specific pharmaceutical application, yet the available market data reveals a diverse array of formulations and packaging configurations that require careful differentiation. The product is fundamentally categorized under inorganic and organic chemical types, as well as biological products, indicating that the supply chain includes various stages of synthesis and processing. The primary state of the product is liquid, which is essential for intravenous administration, ensuring rapid absorption and bioavailability.

The technical specifications vary significantly across different listings, reflecting the modular nature of pharmaceutical manufacturing. A critical observation in the current market is the variation in dosage models. Buyers will encounter specific model identifiers such as "100ml: 500mg," "500mg/100ml," and "100ml: 0.5g." These notations are not merely descriptive but represent the concentration and volume ratios that dictate clinical usage. Furthermore, specific model codes like "AMC15002-01" and "AMC15002-03" suggest distinct batch or production line variations that may influence compatibility with existing infusion protocols. The standard concentrations observed include 0.9% saline solutions, which are standard for isotonic intravenous delivery.

Packaging is another pivotal specification that impacts logistics and storage. The data indicates a range of packaging solutions, from individual plastic bottles to bulk cartons. Some listings specify "1 Bottle/Box" with "80 Boxes/CTN," while others offer "1's/Box" or flexible options described as "as Your Request." The physical dimensions of the cartons are also documented, with a specific example of a carton size measuring 4634.423.5 CM. This data is vital for calculating freight costs and warehouse space requirements. The product origin is consistently noted as Hebei, China, which serves as a primary hub for this type of chemical synthesis and pharmaceutical production.

Compliance Standards and Regulatory Verification

Navigating the regulatory environment is the most critical step in sourcing high-quality intravenous metronidazole. The supply chain is governed by international and domestic standards that ensure the safety and efficacy of the medication. The observed market data explicitly mentions "Bp" (British Pharmacopoeia) and "USP" (United States Pharmacopeia) as available standards. These are not optional add-ons but fundamental benchmarks for quality assurance. Buyers must verify that the specific lot they are purchasing adheres to one of these recognized pharmacopeias, as the absence of such certification can render the product unusable in regulated markets.

The production process itself is subject to strict oversight. The data highlights that the production line is "GMP Approved," which stands for Good Manufacturing Practice. This approval is a prerequisite for any facility manufacturing injectable medicines. GMP certification ensures that the facility maintains consistent quality control, hygiene, and documentation throughout the manufacturing process. Without this, the risk of contamination or batch inconsistency increases significantly. Additionally, the product is classified under HS Code 3004, which is the specific Harmonized System code for medicaments put up in measured doses or in forms or packings for retail sale. This classification is essential for customs clearance and tariff determination.

While the data mentions "Chemical Synthesis" as the pharmaceutical technology, buyers must understand that this process must be validated against the specific standard required by their target market. The standard "100ml 250ml" and "50ml-1000ml" indicate that volume standards are flexible but must be clearly defined in the purchase order. The presence of "Standard Available: Bp, USP" suggests that suppliers may offer different grades, and the buyer must explicitly request the grade that matches their regulatory requirements. It is imperative to confirm that the supplier can provide a Certificate of Analysis (CoA) that references these specific standards for every batch delivered.

Cost Drivers and Pricing Dynamics

The pricing structure for intravenous metronidazole is influenced by a multitude of factors, ranging from raw material costs to logistics and regulatory compliance. The observed price range in the market data is listed as 0-1 USD, which likely represents a unit price for specific bulk configurations or a placeholder for negotiated rates rather than a fixed retail price. This wide range indicates that the final cost is highly dependent on the volume ordered and the specific packaging configuration selected.

The Minimum Order Quantity (MOQ) is a significant driver of unit cost. The data shows an MOQ range from 1 to 1,000,000 units, with a specific high-confidence observation of an MOQ of 50,000 units. This suggests that the market is dominated by bulk transactions, where economies of scale play a crucial role. Buyers ordering at the lower end of the MOQ spectrum may face higher per-unit costs, while those capable of meeting the 50,000-unit threshold can likely negotiate more favorable pricing. The flexibility in packaging, such as "as Your Request," also allows buyers to optimize costs by choosing packaging that minimizes waste and shipping volume.

Logistics costs are another major component. The transport methods observed include "by Sea" and "Shipping," which are standard for international bulk pharmaceutical trade. The lead time is documented as 30-60 days, which is a critical factor in total cost of ownership. This duration includes production, quality testing, customs clearance, and freight. Buyers must factor in the potential for price fluctuations due to fuel surcharges or currency exchange rates over this period. The origin location, Hebei, China, implies that shipping costs will be calculated from this specific region, and buyers should consider the distance to their destination port when budgeting.

Typical Applications and Clinical Indications

The application of intravenous metronidazole is broad, covering several critical areas of modern medicine. The data identifies "Internal Medicine" and "Surgery" as the primary application fields. In internal medicine, the drug is utilized for treating serious infections caused by anaerobic bacteria and protozoa. Its role in surgery is equally vital, often used for prophylaxis against surgical site infections, particularly in gastrointestinal and gynecological procedures where anaerobic flora is prevalent.

The target demographic for this product is diverse, including adults, children, and the elderly. This versatility makes it a staple in hospital formularies across various departments. However, the usage mode is strictly defined as "For external use" in some contexts, which can be confusing. In the context of intravenous injection, this likely refers to the administration route being external to the body (i.e., injected) rather than topical. The specific indication "I.V. Infusion Only" for the 500mg/100ml formulation reinforces that this product is not suitable for oral or topical application, ensuring that procurement teams order the correct formulation for the intended clinical setting.

The function of the product is explicitly labeled as "Antibacterial Medicine" and "Antibacterial," highlighting its primary mechanism of action. It is designed to combat bacterial infections, making it a critical resource in treating conditions such as sepsis, abscesses, and intra-abdominal infections. The dosage form, "Injection," confirms that it is intended for parenteral administration, which bypasses the digestive system for immediate therapeutic effect. Buyers must ensure that their procurement aligns with these clinical indications to avoid the purchase of incorrect formulations that could compromise patient safety.

Supplier Evaluation and Production Capabilities

Evaluating suppliers for intravenous metronidazole requires a deep dive into their production capabilities and customization options. The data indicates that customization is available, and OEM/ODM support is offered, with some listings noting "Supprot" (Support) for these services. This flexibility allows buyers to request specific packaging, labeling, or even slight formulation adjustments to meet local regulatory requirements or brand preferences. The ability to support OEM/ODM suggests that the supplier has the infrastructure to handle private label manufacturing, which is common in large hospital chains or pharmaceutical distributors.

The production line's GMP approval is a non-negotiable criterion for supplier selection. Buyers should verify the validity of this certification and ensure it covers the specific product line being purchased. The origin of the product, Hebei, China, is a known manufacturing hub, but buyers should not assume all facilities in this region meet the same standards. Due diligence is required to confirm that the specific factory producing the batch has the necessary licenses and quality control measures in place.

Transport capabilities are also a key evaluation metric. The data mentions "Transport: by Sea" and "Shipping," indicating that the supplier has experience in international logistics. However, buyers should assess the supplier's ability to handle temperature-sensitive shipments, as intravenous solutions often require specific storage conditions to maintain stability. The lead time of 30-60 days suggests a robust production schedule, but buyers should inquire about the supplier's contingency plans for delays, especially given the potential for supply chain disruptions in the pharmaceutical sector.

Quality Control and Long-Term Procurement Strategy

Maintaining consistent quality is paramount in the procurement of intravenous metronidazole. The observed standards, including Bp and USP, serve as the baseline for quality control. Buyers must insist on receiving a Certificate of Analysis (CoA) for every batch, which should detail the results of tests for purity, potency, and sterility. The product's color is noted as "Transparent," which is a visual indicator of quality, but this should be supplemented with rigorous laboratory testing.

Long-term procurement strategies should focus on building a reliable supply chain that can withstand market fluctuations. The high MOQ of 50,000 units suggests that buyers should consider forming consortia or partnering with other institutions to meet these thresholds and secure better pricing. The flexibility in packaging, such as "80bottle/Carton" or "1's/Box," allows for strategic inventory management, enabling buyers to store products efficiently while minimizing the risk of expiration.

The lead time of 30-60 days necessitates careful inventory planning. Buyers should maintain a safety stock to account for potential delays in production or shipping. Additionally, the availability of customization and OEM/ODM support offers an opportunity to differentiate the supply chain by creating exclusive packaging or labeling that aligns with the buyer's brand or regulatory needs. By focusing on these strategic elements, buyers can ensure a steady, high-quality supply of intravenous metronidazole that meets the clinical needs of their patients while adhering to strict regulatory standards.

Comparative Analysis of Product Attributes

To facilitate decision-making, the following table summarizes the key attributes observed in the market data for intravenous metronidazole. This comparison highlights the variability in specifications and helps buyers identify the most suitable options for their specific needs.

This comparative analysis underscores the importance of aligning procurement specifications with clinical and logistical requirements. By carefully evaluating these attributes, buyers can navigate the complexities of the intravenous metronidazole market and secure a supply chain that ensures patient safety and operational efficiency.